Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS



Date/App# patent app List of recent Antibodies-related patents
07/30/15
20150213229 
 Fault diagnosis method and apparatus patent thumbnailnew patent Fault diagnosis method and apparatus
A fault diagnosis method is provided. The method includes: performing a technological process of a diagnostic object to obtain an online operation data sample; extracting a first set of data in a first predetermined period of time from the online operation data sample set as a detecting antigen; calculating deviations of the detecting antigen and all of normal antibodies in a normal antibody database to obtain a first deviation set; determining whether each deviation in the first deviation set is less than a normal antibody threshold; if each deviation in the first deviation set is less than the normal antibody threshold, determining that the technological process is normal, else determining that there is a fault in the technological process..
Tsinghua University


07/30/15
20150212092 
 Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies patent thumbnailnew patent Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers.
Jyant Technologies, Inc.


07/30/15
20150212085 
 Anti-phospho-akt antibodies patent thumbnailnew patent Anti-phospho-akt antibodies
The present invention relates to antibodies that immunospecifically bind to phospho-akt and certain p-akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders.
Nuclea Biotechnologies, Inc.


07/30/15
20150212083 
 Anti-t. cruzi antibodies and methods of use patent thumbnailnew patent Anti-t. cruzi antibodies and methods of use
The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of trypanosoma cruzi.. .
Abbott Laboratories


07/30/15
20150212069 
 Sperm-specific cation channel, catsper4, and uses therefor patent thumbnailnew patent Sperm-specific cation channel, catsper4, and uses therefor
Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper4) are disclosed. The catsper4 protein is shown to be specifically expressed in sperm.
Children's Medical Center Corporation


07/30/15
20150211032 
 Isolation and characterization of a novel pythium omega 3 desaturase with specificity to all omega 6 fatty acids longer than 18 carbon chains patent thumbnailnew patent Isolation and characterization of a novel pythium omega 3 desaturase with specificity to all omega 6 fatty acids longer than 18 carbon chains
The present invention relates to a polynucleotide encoding an omega 3 (ω-3) desaturase from pythium irregulare with specificity to long chain polyunsaturated omega 6 (ω-6) fatty acids as well as a vector containing the polynucleotide, and a host cell containing the vector or the polynucleotide. Moreover, the present invention pertains to a polypeptide encoded by the polynucleotide, antibodies against the polypeptide as well as a method for the manufacture of the polypeptide.
Bioriginal Food & Science Corp.


07/30/15
20150211020 
 Complex chromosome engineering for production of human antibodies in transgenic animals patent thumbnailnew patent Complex chromosome engineering for production of human antibodies in transgenic animals
The invention relates to large-scale production of human antibodies by transgenic animals with high production of fully human igg up to >10 g/l in sera with human igg1 subclass dominancy. This invention also supports a feasibility of complex chromosome engineering for complicated genetic studies in non-murine mammalian species..
Sab, Llc


07/30/15
20150210775 
 Antibody specific to staphylococcus aureus, therapeutic method and detection method using same patent thumbnailnew patent Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
We provide new monoclonal antibody inhibitors of coagulases for treatment of s. Aureus.

07/30/15
20150210771 
 Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies patent thumbnailnew patent Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.. .

07/30/15
20150210766 
 Anti-her3 scfv fragment and bispecific anti-c-met/anti-her3 antibodies comprising the same patent thumbnailnew patent Anti-her3 scfv fragment and bispecific anti-c-met/anti-her3 antibodies comprising the same
Provided is an anti-her3 antibody or antigen-binding fragment thereof, an anti-c-met/anti-her3 bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same.. .
Samsung Electronics Co., Ltd.


07/30/15
20150210765 
new patent

Multivalent and monovalent multispecific complexes and their uses


Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described..
Zyngenia, Inc.


07/30/15
20150210764 
new patent

Binding proteins and methods of use thereof


The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.. .
Ngm Biopharmaceuticals, Inc.


07/30/15
20150210760 
new patent

Therapeutic pancreatic cancer


The present invention relates to methods and medicarnents useful for treating locally advanced pancreatic cancer (lapc). Improved therapeutic methods and regimens comprising anti-connective tissue growth factor (ctgf) agents, including anti-ctgf antibodies, are provided.
Fibrogen, Inc.


07/30/15
20150210759 
new patent

Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof


Provided are novel human islet amyloid polypeptide, also known as amylin and iapp and proiapp respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for iapp and/or proiapp are also disclosed.
Neurimmune Holding Ag


07/30/15
20150210735 
new patent

Isolation and purification of antibodies using protein a affinity chromatography


Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably protein a affinity, ion exchange chromatography, and hydrophobic chromatography.
Abbvie Inc.


07/30/15
20150209430 
new patent

Antibody formulations and uses thereof


The present application relates to formulations of anti-cd105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-cd105 antibodies or antigen-binding fragments thereof.
Tracon Pharmaceuticals, Inc.


07/30/15
20150209427 
new patent

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof


Novel antibodies and antigen binding fragments that specifically bind to kaag1 and which may be used in the treatment, detection and diagnosis of cancer comprising kaag1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
Alethia Biotherapeutics Inc.


07/30/15
20150209425 
new patent

Iscom preparation and use thereof


The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from quillaja saponaria molina. The complexes may be iscom complexes or iscom matrix complexes.
Novavax Ab


07/30/15
20150209422 
new patent

Immunization with rabies virus vector expressing foreign protein antigen


An immune response in a subject is elicited by a regiment comprising immunization with an attenuated recombinant rabies virus encoding at least one foreign protein antigen, and booster immunization with the at least one foreign protein antigen in a vehicle that does not contain adjuvant. The foreign protein antigen may comprise a prion protein antigen, a cancer-associated antigens, a viral antigen, a bacterial antigens, or a protozoal antigen.
Thomas Jefferson University


07/23/15
20150204879 

Immunological compositions as cancer biomarkers and/or therapeutics


The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example..
Vanderbilt University


07/23/15
20150204868 

Peptides, devices, and methods for the detection of anaplasma antibodies


The invention provides populations of isolated peptides useful for the detection of antibodies that bind to anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the anaplasma outer membrane protein proteins.
Abaxis, Inc.


07/23/15
20150204866 

Auto-antigen biomarkers for lupus


The presence of certain auto-antibodies indicates that a subject has lupus. The auto-antibodies recognise antigens listed in table 1 herein.
Sense Proteomic Limited


07/23/15
20150204857 

Compositions and methods for rapid and reversible biomolecular labeling


This disclosure provides compositions and methods for a low-avidity, high-affinity and high-specificity biomolecular interaction that is rapidly reversible under physiological conditions. The methods comprise linking biological targets (such as molecules, proteins, dna, cells, etc.) with polymers and anti-polymer ligands and a way to reverse their binding using physiologically compatible polymeric compounds.
Stemcell Technologies Inc.


07/23/15
20150203915 

Screening methods for transfusion related acute lung injury (trali)


The invention relates to the discovery that hna-3a and hna-3b are antigens within a polypeptide sequence that is highly similar to the ctl2 amino acid sequence. This invention provides methods and kits for screening for hna-3a and hna-3b specific antibodies, hna-3a and hna-3b polypeptides and hna-3a and hna-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Drk Blutspendedienst West Gmbh


07/23/15
20150203829 

Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk


The present invention concerns an antibody specific for human alk (anaplastic lymphoma kinase), in particular a scfv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma..
Delenex Therapeutics Ag


07/23/15
20150203828 

N-glycan core beta-galactosyltransferase and uses thereof


The present invention relates to new galactosyltransferases, nucleic acids encoding them, as well as recombinant vectors, host cells, antibodies, uses and methods relating thereto.. .
Universitat Zurich


07/23/15
20150203816 

Means and methods for influencing the stability of cells


The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of bcl6 and/or blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines arc also provided, as well as methods for producing antibodies using such cells and/or cell lines..
Aimm Therapeutics B.v.


07/23/15
20150203590 

Lipoprotein-associated phospholipase a2 antibody compositions and methods of use


The invention provides isolated anti-lp-pla2 antibodies that bind to lp-pla2. The invention also encompasses compositions comprising an anti-lp-pla2 antibody.

07/23/15
20150203587 

Anti-cd38 antibodies


Isolated antibodies that bind to human cd38 and cynomolgus cd38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies..
Takeda Pharmaceuticals, Inc.


07/23/15
20150203584 

Anti il-36r antibodies


The present invention relates to anti-il-36r binding compounds, in particular new anti-il-36r antibodies and therapeutic and diagnostic methods and compositions for using the same.. .
Boehringer Ingelheim International Gmbh


07/23/15
20150203582 

Method of generating antibodies


The present invention discloses a reliable and efficient method of generating an antibody which can discriminate between the membrane bound form of an antigen and the soluble form of the same antigen. Said method comprises the steps of: (i) immunizing an animal with a first antigen which comprises either the membrane bound form or the soluble form of the antigen; (ii) administering to the animal an agent which selectively kills rapidly dividing cells; (iii) when the first antigen of step (i) comprises the soluble form, immunizing the animal with a second antigen which comprises the membrane bound form of the antigen, or when the first antigen of step (i) comprises the membrane bound form, immunizing the animal with a second antigen which comprises the soluble form of the antigen; and (iv) screening for an antibody which can bind to the second antigen but which does not bind to the first antigen..
Mab Design Ltd


07/23/15
20150203581 

Novel anti- alpha5 beta1 antibodies and uses thereof


The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.. .
Genentech, Inc.


07/23/15
20150203580 

Human antibodies to pd-l1


The present invention provides antibodies that bind to the t-cell co-inhibitor ligand programmed death-ligand1 (pd-l1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-l1.
Regeneron Pharmaceuticals, Inc.


07/23/15
20150203579 

Human antibodies to pd-1


The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Regeneron Pharmaceuticals, Inc.


07/23/15
20150203578 

Anti-siglec-8 antibodies and methods of use thereof


The invention provides humanized anti-siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-siglec-8 antibodies.. .
Allakos Inc.


07/23/15
20150203574 

Antibodies to il-6 and their uses


antibodies and antigen-binding portions thereof that bind to human il-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions..
Pfizer Inc.


07/23/15
20150203571 

Antibodies to ion channels


An anti-e1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.. .
Ucb Biopharma Sprl


07/23/15
20150203570 

Prevention and treatment of pain using antibodies to sphingosine-1-phosphate


The present invention relates to use of anti-s1p agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain.. .
Lpath, Inc.


07/23/15
20150203548 

Single-domain antibodies with improved thermal stability under cytoplasmic expression


Methods of producing a single-domain antibody (sdab) include causing a bacteria to express the sdab into cytoplasm of the bacteria, wherein the sdab is expressed as a fusion protein with the acid tail of α-synuclein; and then purifying the sdab, wherein the fusion protein is expressed free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation..
The Government Of The United States Of America, As Represented By The Secretary Of The Navy


07/23/15
20150202320 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/23/15
20150202319 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/23/15
20150202235 

Amnion-derived cell compositions, methods of making and uses thereof


The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers.
Stemnion, Inc.


07/16/15
20150198614 

Beclin 1 phosphorylation


antibodies specific for human beclin 1 protein phosphorylated ser234, ser295, tyr229, tyr233 or try352 are useful in diagnosing diseases such as cancer and impaired autophagy. The invention further relates to human beclin 1 mutated at ser234, ser295, tyr229, tyr233 or try352 with a phospho-silencing residue and uses thereof..
Board Of Regents, The University Of Texas System


07/16/15
20150198609 

Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases


In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to pad3 protein.
The Johns Hopkins University


07/16/15
20150198598 

Kit for diagnosing malignant melanoma


Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against gpc3 and a monoclonal antibody against sparc that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.. .
National Cancer Center


07/16/15
20150198593 

Method and system of microfluidic immunoassay using magnetic beads


A microfluidic western blot method and system including a microfluidic western blot method for immunoassay of proteins, the method including introducing a sample including the proteins onto a chip; electrophoretically separating the proteins; binding the separated proteins to beads to form protein-attached beads, the beads being magnetic; flowing the protein-attached beads into a magnetic holding region; applying a magnetic field to the magnetic holding region to fix the protein-attached beads in place within the magnetic holding region; binding primary antibodies to target proteins on the protein-attached beads; binding secondary antibodies to the bound primary antibodies; and detecting the bound secondary antibodies.. .
Caliper Life Sciences, Inc.


07/16/15
20150198591 

Methods for detecting and measuring aggregation


Methods, compositions, systems, and devices are provided for performing and analyzing agglutination assays. In one aspect, methods for image analysis of agglutination assays are provided.
Theranos, Inc.


07/16/15
20150198589 

Use of edta tube with gel in elisa method


The invention relates to elimination of the false negative or defective results obtained as a result of inadequate or no sample collection by the test sampling probes in the analyzers running with full or semi-automatic elisa method in the studies conducted from the serum today in determination of the anti hiv, anti hcv, syphilis antibodies and hbsag antigen by employing elisa (enzyme linked immune sorbent assay) method, one of the serologic methods, in full or semi-automatic analyzers by use of the plasma obtained from edta gel tube.. .

07/16/15
20150197819 

Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy


The invention relates to biomarkers based on gene expression products and methods for determining the efficacy of anti-egfr antibodies in the treatment of egfr expressing cancer. The invention is further related to the prediction of sensitivity or resistance of a patient suffering from egfr expressing cancer to the treatment of said patient with a specific anti-egfr antibody.
Merck Patent Gesellschaft Mit Beschrankter Haftung


07/16/15
20150197579 

Complex-specific antibodies and antibody fragments and its use


The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and thus can be used e.g.
Morphosys Ag


07/16/15
20150197578 

Anti-tie2 antibodies and uses thereof


The present invention provides antibodies that bind to tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human tie2 and block the interaction between tie2 and one or more tie2 ligands such as angiopoietin 1 (ang1), angiopoietin 2 (ang2), angiopoietin 3 (ang3) and/or angiopoietin 4 (ang4).
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197575 

Tumor specific antibody


The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof.
Viventia Bio Inc.


07/16/15
20150197571 

Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use


The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both pd-l1 and pd-l2 and methods of using same. In one aspect, an isolated monoclonal antibody, or antigen-binding fragment thereof, which specifically binds both pd-l1 and pd-l2, is provided.
President And Fellows Of Harvard College


07/16/15
20150197570 

Anti-ilt5 antibodies and ilt5-binding antibody fragments


Disclosed herein are antibodies and ilt5-binding fragments thereof that specifically bind to ilt5, e.g., human ilt5 (hilt5), and pharmaceutical compositions comprising such ilt5-binding antibodies and ilt5-binding fragments thereof.. .
Merck Sharp & Dohme Corp.


07/16/15
20150197569 

Anti-kir antibodies, formulations, and uses thereof


A novel igg4 isotype anti-kir antibody, novel formulations of this and other igg4 anti-kir antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for nk cell activation and therapeutic applications of anti-kir antibodies, as well as kits comprising one or more anti-kir antibodies with instructions for use in treating cancer..
Novo Nordisk A/s


07/16/15
20150197567 

Antibodies to il-6 and use thereof


The present invention is directed to antibodies and fragments thereof having binding specificity for il-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vii, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Alderbio Holdings Llc


07/16/15
20150197566 

Polynucleotides encoding antagonists of il-17a, il-17f, and il-23p19


The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a, il-17f, and il-23. Antagonists include antibodies and antibody fragments that bind il-23 and that bind il-17a or il-17f, such as antibodies that are cross-reactive for il-17a and il-17f.
Zymogenetics, Inc.


07/16/15
20150197564 

Anti-angptl3 antibodies and uses thereof


A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hangptl3) is provided. The human anti-hangptl3 antibodies are useful in treating diseases or disorders associated with angptl3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197563 

Notch binding agents and antagonists and methods of use thereof


The present invention relates to notch-binding agents and notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human notch receptor, such as notch2 and/or notch3, and inhibit tumor growth.
Oncomed Pharmaceuticals, Inc.


07/16/15
20150197562 

Novel anti-plasmodium parasite antibodies


The technology provided herein relates to novel human antibodies against plasmodium parasites, in particular against the malaria parasite plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (msp10).
Fraunhofer-gesellschaft Zur Foerderung Der Angewa- Ndten Forschung E.v.


07/16/15
20150197561 

Jagged-binding agents and uses thereof


The present invention relates to jagged-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of human jagged1 or human jagged2 and modulate jagged activity.
Oncomed Pharmaceuticals, Inc.


07/16/15
20150197560 

Humanized anti-beta7 antagonists and uses therefor


The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.. .
Genentech, Inc.


07/16/15
20150197559 

Antibodies that neutralize botulinum neurotoxins


This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., bont/a, bont/b, bont/e, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism..
The Regents Of The University Of California


07/16/15
20150197558 

Binding moieties for biofilm remediation


Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species and decoy nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described.
Trellis Bioscience, Llc


07/16/15
20150197557 

Mice that make heavy chain antibodies


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of an igg, iga, igd, and/or ige, and wherein the mouse is capable of expressing a functional igm. Genetically modified mice are described, including mice having a functional igm gene and modified to have a deletion of a ch1 domain and a hinge region in a heavy chain constant domain that is not an igm, e.g., in an igg heavy chain constant domain.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197556 

Mice that make heavy chain antibodies


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of an igg, iga, igd, and/or ige, and wherein the mouse is capable of expressing a functional igm. Genetically modified mice are described, including mice having a functional igm gene and modified to have a deletion of a ch1 domain and a hinge region in a heavy chain constant domain that is not an igm, e.g., in an igg heavy chain constant domain.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197555 

Mice that make heavy chain antibodies


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of an igg, iga, igd, and/or ige, and wherein the mouse is capable of expressing a functional igm. Genetically modified mice are described, including mice having a functional igm gene and modified to have a deletion of a ch1 domain and a hinge region in a heavy chain constant domain that is not an igm, e.g., in an igg heavy chain constant domain.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197554 

Mice that make heavy chain antibodies


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of an igg, iga, igd, and/or ige, and wherein the mouse is capable of expressing a functional igm. Genetically modified mice are described, including mice having a functional igm gene and modified to have a deletion of a ch1 domain and a hinge region in a heavy chain constant domain that is not an igm, e.g., in an igg heavy chain constant domain.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197553 

Mice that make heavy chain antibodies


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of an igg, iga, igd, and/or ige, and wherein the mouse is capable of expressing a functional igm. Genetically modified mice are described, including mice having a functional igm gene and modified to have a deletion of a ch1 domain and a hinge region in a heavy chain constant domain that is not an igm, e.g., in an igg heavy chain constant domain.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150196666 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196665 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196664 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196663 

Blood-brain barrier targeting antibodies


A bbb-selective antibody comprising a protein encoded by seq id no:1 or 3 or comprising a peptide encoded by cdr h1, cdr h2, cdr h3, cdrl1, cdrl2 or cdrl3 of seq id no:1 or cdr h1, cdr h2, cdr h3, cdrl1, cdrl2, or cdrl3 of seq id no: 3 is disclosed.. .
Wisconsin Alumni Research Foundation


07/16/15
20150196662 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196661 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196660 

Anti-etbr antibodies and immunoconjugates


The invention provides anti-etbr antibodies and immunoconjugates and methods of using the same. In some embodiments, an immunoconjugate comprising an antibody that binds etbr covalently attached to a cytotoxic agent is provided, wherein the antibody binds an epitope within amino acids 64 to 101 of seq id no: 10.
Genentech, Inc.


07/16/15
20150196654 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196653 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196642 

Antibody formulations


The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain ii of her2 (for example, pertuzumab), and a formulation comprising an antibody that binds to dr5 (for example, apomab).. .
Genentech, Inc.


07/16/15
20150196015 

Mice that make heavy chain antibodies


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of an igg, iga, igd, and/or ige, and wherein the mouse is capable of expressing a functional igm. Genetically modified mice are described, including mice having a functional igm gene and modified to have a deletion of a ch1 domain and a hinge region in a heavy chain constant domain that is not an igm, e.g., in an igg heavy chain constant domain.
Regeneron Pharmaceuticals, Inc.


07/09/15
20150192591 

Method of simultaneous detection of heparin-induced immunoglobulins types g, a and m


The invention provides a method for detecting heparin-induced antibodies comprising a) binding a pf4-heparin antigen to a solid surface; b) incubating the bound pf4-heparin with a sample comprising heparin-induced antibodies to be detected; c) contacting the sample with at least two labeled secondary antibodies, wherein the secondary antibodies bind to heparin-induced antibodies present in the sample; d) detecting the presence of the labeled secondary antibodies using flow cytometry or a suitable method, wherein the heparin-induced antibodies bound to the secondary antibodies are identified. In one embodiment, the at least two secondary antibodies are anti-human antibodies which specifically bind to heparin-induced antibodies and are selected from the group consisting of ig, igg, iga, and igm..
Bloodcenter Research Foundation, Inc.


07/09/15
20150192584 

Methods for liquid direct fluorescent antibody intracellular virus detection


The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus.
Diagnostic Hybrids, Inc.


07/09/15
20150192581 

Lateral flow device for diagnosing microbial infections


Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carriers with it a high mortality.
The Johns Hopkins University


07/09/15
20150192580 

Biomarker for neurodegeneration in neurological disease


A method of detecting or diagnosing a neurodegenerative disease in a subject by an immunoassay is provided. The immunoassay comprises obtaining a sample from a subject and assaying the sample for the presence of autoantibodies against certain epitopes of heterogeneous nuclear ribonuclear protein a1 (hnrnp a1).

07/09/15
20150192576 

Methods and reagents for prevention and/or treatment of transplant rejection


The present invention relates to methods for determining the probability of transplant rejection based on the determination in the subject recipient of the transplant of the levels of antibodies specific for hyaluronic acid. The invention relates as well to methods for attenuating transplant rejection and compositions to prevent transplant rejection based on the depletion of anti-hyaluronic acid antibodies from the subject..
Fundacio Institut D'investigacio Biomedica De Bellvitge (idibell)


07/09/15
20150191548 

Antibodies comprising sequences from camelidae to highly conserved targets


The present invention is concerned with antigen binding polypeptides, and in particular conventional antibodies derived from camelid species, that specifically bind to target antigens that are either self-antigens or highly conserved antigens. The present invention also relates to anti-idiotype antigen binding peptides which bind to a target antigen comprising the variable region of an antibody obtained from a species within the family camelidae..
Argen-x B.v.


07/09/15
20150191547 

Human anti-kir antibodies


Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of nk cells and allow a potentiation of nk cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7f9 or 1-4f1.
University Of Genoa


07/09/15
20150191546 

Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease


The specification describes the sequences for antibodies that recognize the hla-a2-restricted peptide pr-1 in the context of hla presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided..
Board Of Regents, The University Of Texas System


07/09/15
20150191543 

Engineered antibody fragments for targeting and imaging cd8 expression in vivo


Disclosed herein, the parental antibodies from the hybridomas yts 169.4.2.1 (yts169) and 2.43 were engineered into minibody and diabody fragments. Both the yts and 2.43 antibodies bind mcd8+.
The Regents Of The University Of California


07/09/15
20150191542 

Mica binding agents


The present invention relates to methods for the treatment of disorders mediated by mica-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind mica. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same..
Innate Pharma, S.a.


07/09/15
20150191541 

Antibodies that recognize iapp


The invention provides monoclonal antibody 8a9 and related antibodies. The 8a9 antibody binds to an epitope within residues 1-10 of iapp.
Neotope Biosciences Limited


07/09/15
20150191537 

Antibodies specific for sclerostin and methods for increasing bone mineralization


Compositions and methods relating to antibodies that specifically bind to tgf-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a tgf-beta binding protein sclerostin and a tgf-beta superfamily member, particularly a bone morphogenic protein.
Ucb Pharma S.a.


07/09/15
20150191535 

Bispecific, bivalent anti-vegf/anti-ang2 antibodies


The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (vegf/vegf-a) and against human angiopoietin-2 (ang-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche Inc.


07/09/15
20150191534 

Human antibodies to human delta like ligand 4


The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hdll4) and blocks hdll4 binding to a notch receptor. The anti-hdll4 antibody or fragment thereof of the present invention have a high affinity with the kd of 500 pm or less, as measured by surface plasmon resonance..
Regeneron Pharmaceuticals, Inc.


07/09/15
20150191531 

Compositions and methods for the therapy and diagnosis of cytomegalovirus infections


The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection..
Theraclone Sciences, Inc.


07/09/15
20150191529 

Removal of impurities from protein a eluates


Modified protein a, protein g, protein l, or protein a/g that lacks antibody binding activity, and methods of the modified protein's use for purifying antibodies is provided.. .
Bio-rad Laboratories, Inc.


07/09/15
20150191520 

Complement split product c4d for the treatment of inflammatory conditions


The present invention relates to a pharmaceutical composition comprising complement split product c4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The c4d to be used may be a multimer.
Medizinische Universität Wien


07/09/15
20150191514 

Hyr1-derived compositions and methods of treatment using same


The disclosure features isolated polypeptides of hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or acinetobacter infections or both.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


07/09/15
20150190514 

Stabilizing polypeptides which have been exposed to urea


Methods for stabilizing polypeptides, such as anti-her2 antibodies, which have been exposed to urea.. .
Genentech, Inc.




Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5904

4653

1 - 1 - 101